Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection
Runcong Zhang, Jing Fan, Lu Han, Juehui Mao, Liang Sun, Yuetian Yu, Weibin Fan, Jiao Xie, Bin Lin, Nengming Lin · 2024
Read Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection by Runcong Zhang, Jing Fan, Lu Han, Juehui Mao, Liang Sun, Yuetian Yu, Weibin Fan, Jiao Xie, Bin Lin, Nengming Lin (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11622681.txt.
Description
Runcong Zhang and co-authors model how the COVID-19 drug nirmatrelvir behaves in Chinese patients in a 2024 paper. The drug, paired with ritonavir, was the first to win emergency approval for the infection. Doses were set broadly, yet body traits may shift drug levels a lot. The team built a population model to find what matters and to tune dosing.
They drew sparse blood samples from close to one hundred thirty patients on the standard five-day course. A simple one-compartment model fit the data best. Kidney function and body weight stood out as the traits that shape drug exposure. Simulations for virtual patients across weight and kidney ranges then guided dose choices. The group also built a web dashboard that shows drug levels over time and suggests a personal dose.
Catalog record
| CREATOR | Runcong Zhang, Jing Fan, Lu Han, Juehui Mao, Liang Sun, Yuetian Yu, Weibin Fan, Jiao Xie, Bin Lin, Nengming Lin |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |